LDK1229

CAS No. 1800285-55-5

LDK1229 ( LDK 1229 )

Catalog No. M12734 CAS No. 1800285-55-5

LDK1229 is a novel potent, selective cannabinoid CB1 receptor inverse agonist with Ki of 220 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    LDK1229
  • Note
    Research use only, not for human use.
  • Brief Description
    LDK1229 is a novel potent, selective cannabinoid CB1 receptor inverse agonist with Ki of 220 nM.
  • Description
    LDK1229 is a novel potent, selective cannabinoid CB1 receptor inverse agonist with Ki of 220 nM; exhibits 3-fold relative selectivity for the CB1 over CB2, exhibits efficacy comparable with SR141716A in antagonizing the basal G protein coupling activity of CB1; increases cell surface localization of CB1 and structurally distinct from the first-generation CB1 inverse agonists.
  • Synonyms
    LDK 1229
  • Pathway
    GPCR/G Protein
  • Target
    Cannabinoid Receptor
  • Recptor
    Cannabinoid Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1800285-55-5
  • Formula Weight
    434.96
  • Molecular Formula
    C24H29ClF2N2O
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    (4-(Bis(4-fluorophenyl)methyl)piperazin-1-yl)(cyclohexyl)methanone hydrochloride

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Mahmoud MM, et al. Mol Pharmacol. 2015 Feb;87(2):197-206.
molnova catalog
related products
  • GW405833 hydrochlori...

    A potent, selective cannabinoid receptor CB2 agonist with Ki of 3.6 nM, 1200-fold selectivity over CB1.

  • MN-25

    A potent, reasonably selective agonist of peripheral cannabinoid receptor.

  • NESS-040C5

    A potent, reasonably selective cannabinoid CB2 agonist with Ki of 0.4 nM, 25-fold selectivity over CB1 receptor.